Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD40LG	Synonyms	CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L	Type of gene	protein-coding
Chromosome	X	Map location	Xq26.3	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	CD40 ligand

Gene symbol	CD70	Synonyms	CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A	Type of gene	protein-coding
Chromosome	19	Map location	19p13.3	dbXrefs
Description	CD70 molecule

Gene symbol	TLR4	Synonyms	ARMD10, CD284, TLR-4, TOLL	Type of gene	protein-coding
Chromosome	9	Map location	9q33.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	toll like receptor 4

GTO ID	GTC0331
Trial ID	NCT02888756
Disease	HIV Infection
Altered gene	CD40LG\|TLR4\|CD70
Therapeutic/Target gene	Therapeutic gene
Therapy	mRNA vaccine
Treatment	iHIVARNA-01
Phase	Phase2
Recruitment status	Terminated
Title	A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy
Year	2017
Country	Belgium\|Netherlands\|Spain
Company sponsor	Rob Gruters
Other ID(s)	iHIVARNA phase II\|2016-002724-83

Vector information

Vector	dendritic cell

Clinical Result

Cohort1: TriMix mRNA_HIV mRNA

Administration route	intranodal administration
Dosage	TriMix mRNA, 300 μg; HIV mRNA, 900 μg; 3 vaccinations, two weeks interval
Pts	16
Age	Adult, Older_Adult
Outcome	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0: 0\|Immunogenicity as Measured by Elispot: -0.07(week 6); -0.08(week 18)
Adverse reactions	0/16(All-cause mortality); 2/16(Gastrointestinal disorders)
References	PMID: 31208472

Cohort2: TriMix mRNA

Administration route	intranodal administration
Dosage	TriMix, 300μg, 3 vaccinations, two weeks interval
Pts	9
Age	Adult, Older_Adult
Outcome	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0: 0\|Immunogenicity as Measured by Elispot: 0.18(week 6); -0.12(week 18)
Adverse reactions	No serious clinical adverse events
References	PMID: 31208472

Cohort3: Placebo

Administration route	intranodal administration
Dosage	Water, 3 vaccinations, two weeks interval
Pts	8
Age	Adult, Older_Adult
Outcome	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0: 0\|Immunogenicity as Measured by Elispot: 0.01(week 6); 0.45(week 18)
Adverse reactions	0/8(All-cause mortality); 1/8(Psychiatric disorders)
References	PMID: 31208472

Relationship Graph

Overview of Knowledge Graph